Table 3. Summary of pharmacokinetic analyses for IM and panobinostat.
| PK parameter | Concentration (ng ml−1) (± s.e.m.) | Concentration (±s.e.m.) |
|---|---|---|
|
Panobinostat Cmax (mean) at 20 mg | ||
| D1 | 12.6 (±3.6) | 36.1 nM (±10.3 nM) |
| D8 | 16.6 (±2.3) | 47.5 nM (±16.6 nM) |
| D15 |
15.6 (±3.8) |
44.6 nM (±10.9 nM) |
| IM Cmax (mean):
(P=0.185) |
2068 (±310) (without pan)
2564 (±190) (with pan) |
3.5 μM (±0.5 μM) (without pan)
4.3 μM (±0.3 μM) (with pan) |
| IM terminal half-life: |
20.5 h (with pan) |
|
| IM trough levels: (mean) (P=0.125) | 1085 (±480) (without pan) 1290 (±440) (with pan) | 1.8 μM (±0.8 μM) (without pan) 2.2 μM (±0.7 μM) (with pan) |